LONDON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented ...
To get an idea of why investors and analysts are excited about Irvine-based Edwards Lifesciences Corp.’s latest heart valve, look to Europe. The company’s Sapien valve, which is inserted via a ...
The Food and Drug Administration Wednesday approved Irvine-based Edwards Lifesciences Corp.’s Sapien 3 less-invasive heart valve. Sapien 3 is approved for patients with narrowing aortic heart valves ...
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach ...
IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment ...
Edwards Lifesciences Corporation EW recently launched the SAPIEN 3 Ultra RESILIA valve post the FDA approval of the same. The SAPIEN 3 Ultra RESILIA valve comprises the breakthrough RESILIA tissue ...
Edwards Lifesciences (NYSE:EW) today announced 10-year results from the COMMENCE aortic trial supporting its proprietary ...
CHICAGO (Reuters) - Edwards LifeSciences Corp's less-invasive replacement heart valve alleviates symptoms such as fatigue and breathlessness better than standard medical therapy, data released on ...
SAN FRANCISCO, Oct. 24, 2023 /PRNewswire/ -- Edwards Lifesciences (EW) today announced new data from the PARTNER 3 trial demonstrating continued low rates of all-cause mortality, disabling stroke and ...
Late Wednesday, a U.S. Food and Drug Administration panel recommended that Edwards Lifesciences (NYSE:EV) transcatheter aortic valve replacement procedure be approved for patients with high risk to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results